Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Blood Therapeutics Inc.

www.globalbloodtx.com

Latest From Global Blood Therapeutics Inc.

Pipeline Watch: Phase III Trials Initiated For AMT-061, RP-G28 And APL-2

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Global Blood Makes Case For Accelerated Approval Of Sickle Cell Drug Voxelotor

Plan to pursue accelerated approval carries risk that US FDA will ask for more data, which could significantly delay the launch, some analysts warn.

FDA Blood & Coagulation Disorders

Pipeline Watch – Updates From EULAR, EHA and ECNP

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Clinical Trials

Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst

The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.

Business Strategies Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Global Blood Therapeutics Inc.
  • Senior Management
  • Ted W Love, MD, CEO
    Jeffrey Farrow, CFO
    Jung E Choi, Chief Bus. & Strategy Officer
    Hing Sham, PhD, SVP, Research
    David L Johnson, Chief Commercial Officer
  • Contact Info
  • Global Blood Therapeutics Inc.
    Phone: (650) 741-7700
    171 Oyster Point Blvd.
    Ste. 300
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register